ArticleFrontiers in pharmacology2026

Rivaroxaban suppresses factor Xa-Driven PAR-2-ERK inflammatory, catabolic, osteoclastogenic, and mitochondrial dysfunction signaling in osteoarthritis-relevant chondrocytes: a drug-repurposing strategy for joint inflammation.

Rajashree Patnaik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.